Abstract
The contract biomanufacturing market achieved a value of $2.5bn in 2006, with
growth expected to continue at an annual rate of 0- 5% until at least 20. The
proportion of biologics in new drug approvals has risen by over 30% during the
last decade, and with the current pipeline containing more than 500 protein
and 50 peptide developmental drugs, this trend is set to continue. The
commercial success of over 350 approved biologics has prompted the
biotechnology industry to accelerate discoveries in further protein-based
therapeutics, placing greater emphasis upon the importance of
biomanufacturing. Many biotechnology companies are faced with limited
resources, and as large-scale manufacturing continues to intensify, deciding
whether it should be internalised or outsourced to partners or CMO' s is
increasingly crucial in the development of a biotech firm. Biomanufacturing
Strategies is a new report published by Business Insights that examines the
future direction of biomanufacturing through a detailed analysis of market
drivers, restraints and trends.
The production strategies and capacities of leading biopharma companies are
assessed, and growth forecasts for microbial fermentations and mammalian cell
culture are provided. This report will also detail the tactical balance
required between a firm' s potential manufacturing capability and overall
corporate strategy, in addition to profiling other key factors that bear
crucial importance to the ‘build vs buy' decision. Use this report to
identify the key criteria involved in CMO selection, compare the expansion
strategies and capacity shares of leading players and analyse the growth
drivers shaping the future of biomanufacturing.
| 
View Cart
